Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells

BMC Cardiovascular Disorders

Volumn 5, Issue , 2005, Pages

  Zhu, Shengsi ^a,b   Viswambharan, Hema ^a   Gajanayake, Thusitha ^a   Ming, Xiu Fen ^a   Yang, Zhihong ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; RAPAMYCIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THROMBOPLASTIN; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; MTOR PROTEIN, HUMAN; PROTEIN KINASE; TARGET OF RAPAMYCIN KINASE;

AORTA; ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; METABOLISM;

AORTA; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASES; SAPHENOUS VEIN; SIROLIMUS; THROMBOPLASTIN; TOR SERINE-THREONINE KINASES;

EID: 26844528570     PISSN: 14712261     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-5-22     Document Type: Article

References (36)

1. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van LG, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001, 104:2007-2011.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
4. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003, 362:1093-1099.
5. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004, 109:190-195.
6. Popma JJ, Leon MB, Moses JW, Holmes DR, Jr., Cox N, Fitzpatrick M, Douglas J, Lambert C, Mooney M, Yakubov S, Kuntz RE: Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004, 110:3773-3780.
7. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wulfert E: Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005, 111:1040-1044.
8. Poon M, Badimon JJ, Fuster V: Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002, 359:619-622.
9. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ: A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004, 364:583-591.
10. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW: Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005, 45:947-953.
11. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C: Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005, 45:954-959.
12. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004, 364:1519-1521.
13. Moons AH, Levi M, Peters RJ: Tissue factor and coronary artery disease. Cardiovasc Res 2002, 53:313-325.
14. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP: Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005, 105:192-198.
15. Archipoff G, Beretz A, Freyssinet JM, Klein-Soyer C, Brisson C, Cazenave JP: Heterogeneous regulation of constitutive thrombomodulin or inducible tissuefactor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J 1991, 273:679-684.
16. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002, 105:1756-1759.
17. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergeres G, Rusconi S, Yang Z: Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 2004, 94:918-925.
18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
19. Farmer JA: Pleiotropic effects of statins. Curr Atheroscler Rep 2000, 2:208-217.
20. Yang Z, Kozai T, van der LB, Viswambharan H, Lachat M, Turina MI, Malinski T, Luscher TF: HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000, 36:1691-1697.
21. Ming XF, Burgering BM, Wennstrom S, Claesson-Welsh L, Heldin CH, Bos JL, Kozma SC, Thomas G: Activation of p70/p85 S6 kinase by a pathway independent of p21ras. Nature 1994, 371:426-429.
22. Kerner A, Gruberg L, Kapeliovich M, Grenadier E: Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 2003, 60:505-508.
23. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004, 109:701-705.
24. Eisenberg MJ: Drug-eluting stents: some bare facts. Lancet 2004, 364:1466-1467.
25. Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis CA, Hoye A, van DM, Sianos G, Smits PC, de FP, van der Giessen WJ, van Domburg RT, Serruys PW: Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003, 41:2093-2099.
26. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR, Jr., Spanos V, Louvard Y, Desmedt B, Di MC, Leon MB: Randomized study to evaluate sirolimuseluting stents implanted at coronary bifurcation lesions. Circulation 2004, 109:1244-1249.
27. Murphy BE: Drug-eluting stents: some first-generation problems. Am Heart Hosp J 2004, 2:80-84.
28. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP: Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002, 21:990-998.
29. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E: Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998, 13:3153-3159.
30. Walpoth BH, Pavlicek M, Celik B, Nicolaus B, Schaffner T, Althaus U, Hess OM, Carrel T, Morris RE: Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001, 19:487-492.
31. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T, Virmani R: Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003, 107:1340-1341.
32. Fukuda D, Sata M, Tanaka K, Nagai R: Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005, 111:926-931
33. Iakovou I, Sangiorgi GM, Stankovic G, Corvaja N, Vitrella G, Ferraro M, Colombo A: Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient. Catheter Cardiovasc Interv 2005, 64:436-439
34. Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK, Jauch KW, Bruns CJ: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005. Jan 25; [Epub ahead of print]
35. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003, 23:729-736.
36. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.